Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 27, 2010
Event Date: December 23, 2010
Context: The filing discloses a government grant awarded to the Company's wholly owned Israeli subsidiary, Oramed Ltd, under Regulation FD.
Key Financial Metrics
Grant Award: 2.9 million NIS (approximately $807,000 USD).
Grant Period: July 2010 to June 2011.
Grant Purpose: Government participation in research and development (R&D) expenses.
Revenue/Profit/Cash Flow: The filing text does not provide a clear value for overall revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the receipt of the grant from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. This represents new non-dilutive funding for R&D activities.
Outlook, Risks, and Contingencies
- Contingency: The grant is subject to return according to the terms determined by the OCS.
- Management Commentary: The filing references a press release (Exhibit 99.1) for further details but does not include additional management commentary within the text of the 8-K.
- Risks: The primary risk associated with this item is the potential obligation to return funds if OCS terms are not met.
Investor Verification Checklist
- Verify the specific terms and conditions under which the 2.9 million NIS grant may be required to be returned.
- Confirm the accounting treatment of the grant (e.g., recognition timing) in the Company's financial statements.
- Review the attached Press Release (Exhibit 99.1) for detailed project scope covered by the grant.